Atara Biotherapeutics, Inc. (NASDAQ:ATRA) CFO Sells $28,084.95 in Stock

Atara Biotherapeutics, Inc. (NASDAQ:ATRAGet Rating) CFO Utpal Koppikar sold 6,255 shares of Atara Biotherapeutics stock in a transaction dated Wednesday, November 16th. The shares were sold at an average price of $4.49, for a total value of $28,084.95. Following the completion of the transaction, the chief financial officer now directly owns 191,334 shares in the company, valued at $859,089.66. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Atara Biotherapeutics Stock Down 0.9 %

Shares of NASDAQ:ATRA opened at $4.27 on Monday. The company has a 50 day moving average of $4.24 and a two-hundred day moving average of $4.86. Atara Biotherapeutics, Inc. has a 52-week low of $2.83 and a 52-week high of $18.85. The company has a market capitalization of $405.13 million, a price-to-earnings ratio of -1.73 and a beta of 1.02.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Nisa Investment Advisors LLC increased its stake in Atara Biotherapeutics by 893.8% during the 3rd quarter. Nisa Investment Advisors LLC now owns 6,460 shares of the biotechnology company’s stock worth $28,000 after buying an additional 5,810 shares during the period. US Bancorp DE grew its stake in shares of Atara Biotherapeutics by 6,394.9% during the third quarter. US Bancorp DE now owns 7,664 shares of the biotechnology company’s stock valued at $29,000 after acquiring an additional 7,546 shares in the last quarter. First Republic Investment Management Inc. purchased a new stake in shares of Atara Biotherapeutics during the third quarter worth about $38,000. Lazard Asset Management LLC acquired a new position in shares of Atara Biotherapeutics in the third quarter worth about $45,000. Finally, Two Sigma Investments LP purchased a new position in Atara Biotherapeutics in the third quarter valued at about $45,000.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the stock. Mizuho reduced their price target on shares of Atara Biotherapeutics from $39.00 to $31.00 and set a “buy” rating on the stock in a research report on Tuesday, August 16th. The Goldman Sachs Group reduced their target price on shares of Atara Biotherapeutics from $4.00 to $3.00 and set a “sell” rating on the stock in a report on Tuesday, August 9th. Finally, StockNews.com began coverage on Atara Biotherapeutics in a report on Wednesday, October 12th. They issued a “hold” rating for the company. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $18.71.

Atara Biotherapeutics Company Profile

(Get Rating)

Atara Biotherapeutics, Inc is an allogeneic T-cell immunotherapy company, which pioneers the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. also delivers off-the-shelf treatments to patients with high unmet medical need.

Featured Stories

Insider Buying and Selling by Quarter for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.